Related Experiment Video
Updated: May 18, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer
Manish Kohli1, Rui Qin, Rafael Jimenez
1Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Abstract:
Recent therapeutic advances for managing advanced prostate cancer include the successful targeting of the androgen-AR axis with several new drugs in castrate resistant prostate cancer including abiraterone acetate and enzalutamide (MDV3100). This translational progress from "bench to bed-side" has resulted in an enlarging repertoire of novel and traditional drug choices now available for use in advanced prostate cancer therapeutics, which has had a positive clinical impact in prolonging longevity and quality of life of advanced prostate cancer patients. In order to further the clinical utility of these drugs, development of predictive biomarkers guiding individual therapeutic choices remains an ongoing challenge. This paper will summarize the potential in developing predictive biomarkers based on the pathophysiology of the androgen-AR axis in tumor tissue from patients with advanced prostate cancer as well as inherited variation in the patient's genome. Specific examples of rational clinical trial designs incorporating potential predictive biomarkers from these pathways will illustrate several aspects of pharmacogenetic and pharmacogenomic predictive biomarker development in advanced prostate cancer therapeutics.
Insights
New drugs targeting the androgen-AR axis improve advanced prostate cancer outcomes. Developing predictive biomarkers is crucial for personalized treatment selection in castrate-resistant prostate cancer.
Area of Science:
- Oncology
- Pharmacogenomics
- Translational Medicine
Background:
- Advanced prostate cancer management has improved with androgen-AR axis inhibitors like abiraterone acetate and enzalutamide.
- These therapies have extended survival and enhanced quality of life for patients with castrate-resistant prostate cancer.
Purpose of the Study:
- To explore the development of predictive biomarkers for advanced prostate cancer therapeutics.
- To guide individualized treatment choices by leveraging tumor and germline genetic information.
Main Methods:
- Reviewing the pathophysiology of the androgen-AR axis in advanced prostate cancer.
- Analyzing inherited genetic variations in patients.
- Illustrating biomarker development through rational clinical trial designs.
Main Results:
- Successful targeting of the androgen-AR axis has yielded effective treatments for advanced prostate cancer.
- Predictive biomarkers are essential for optimizing the clinical utility of current and future therapies.
Conclusions:
- Pharmacogenomic and pharmacogenetic approaches hold significant potential for predictive biomarker development in advanced prostate cancer.
- Integrating biomarker strategies into clinical trials will refine personalized treatment selection and improve patient outcomes.
More Related Videos
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
